Study Enrollment

Your details will not be published or shared.

Clinical Trial

4020-01-001: A Phase 1 Dose Escalation and Cohort Expansion Study of TSR-022, an anti-TIM-3 Monoclonal Antibody, in Patients with Advanced Solid Tumors (AMBER)

This study is being done to learn more about TSR-022 and its effect on cancer when used either alone or in combination with one other investigational drug called Dostarlimab (TSR-042). TSR-022 given alone or in combination with TSR-042 is considered investigational. This study is divided into 2 parts; participants are being asked to participate in Part 2 cohort D of this study. Part 2 cohort D will enroll patients with advanced non-small cell lung cancer (NSCLC) who have received a specific type of prior cancer treatment and have a certain expression of a tumor marker as determined by testing biopsy tissue.

Eligibility Criteria

  • Male or female, aged 18 years or older Patients with advanced or metastatic Non-Small Cell Lung Cancer that is measurable by CT or MRI

Contact Information

    Kelly Jenkins, RN, MSN, CNL

    (706) 721-1206